uniQure CMO sells 30,000 shares, exercises options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an exercise-and-sell transaction in Ordinary Shares. On June 30, 2026, he sold a total of 30,000 Ordinary Shares in open-market sales at weighted average prices of $46.40 and $46.46 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on September 26, 2025.
On the same date, he exercised stock options to acquire 10,000 Ordinary Shares at a $5.59 exercise price, reducing his option position tied to that grant. Following these transactions, he directly owns 148,235 Ordinary Shares and holds 50,500 stock options expiring on March 1, 2034.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Abi-Saab Walid
Role
Chief Medical Officer
Sold
30,000 shs ($1.39M)
Approx. gross sale proceeds
$1.39M
Approx. exercise cost
$56K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 10,000 | $5.59 | $56K |
| Sale | Ordinary Shares | 10,000 | $46.46 | $465K |
| Sale | Ordinary Shares | 20,000 | $46.40 | $928K |
Holdings After Transaction:
Stock Option (Right to Buy) — 50,500 contracts (Direct);
Ordinary Shares — 148,235 shares (Direct)
Footnotes (4)
- F1. The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.19 to $46.97. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.24 to $46.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnote.
- F4. The Stock Option was granted on March 1, 2024 and vested 25% on the first anniversary of the date of grant, and vests 6.25% quarterly thereafter until fully vested.
Key Figures
Shares sold at $46.40: 20,000 shares at $46.40
Shares sold at $46.46: 10,000 shares at $46.46
Options exercised: 10,000 shares at $5.59
+3 more
6 metrics
Shares sold at $46.40
20,000 shares at $46.40
Ordinary Shares sold June 30, 2026
Shares sold at $46.46
10,000 shares at $46.46
Ordinary Shares sold June 30, 2026
Options exercised
10,000 shares at $5.59
Stock options exercised into Ordinary Shares
Shares owned after transactions
148,235 shares
Direct Ordinary Share holdings after June 30, 2026
Options remaining
50,500 stock options
Options with $5.59 exercise price expiring March 1, 2034
Option expiration date
March 1, 2034
Expiration of reported stock option grant
Key Terms
Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Ordinary Shares
4 terms
Rule 10b5-1 regulatory
"adopted by the Reporting Person on September 26, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of $5.59 per share and expiration date March 1, 2034"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did uniQure (QURE) Chief Medical Officer Walid Abi-Saab report in this Form 4?
He reported an exercise-and-sell sequence involving uniQure Ordinary Shares. On June 30, 2026, he exercised 10,000 stock options at $5.59 per share, then sold 30,000 Ordinary Shares in open-market transactions at weighted average prices of $46.40 and $46.46.
What options did the uniQure (QURE) CMO exercise in this filing?
He exercised stock options covering 10,000 Ordinary Shares at a $5.59 exercise price. These options were granted on March 1, 2024, vesting 25% after one year and 6.25% quarterly thereafter, and are scheduled to expire on March 1, 2034 if unexercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates